MX2019008529A - Peptidos mimeticos de apolipoproteina c-ii (apoc-ii). - Google Patents

Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).

Info

Publication number
MX2019008529A
MX2019008529A MX2019008529A MX2019008529A MX2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A MX 2019008529 A MX2019008529 A MX 2019008529A
Authority
MX
Mexico
Prior art keywords
apoc
apolipoprotein
mimetic peptides
mimetic
peptides
Prior art date
Application number
MX2019008529A
Other languages
English (en)
Spanish (es)
Inventor
N Devalaraja Madhav
Thomas Remaley Alan
Shanker Ghosh Soumitra
O Sviridov Denis
Wolska Anna
Hung Lo Chih-
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2019008529A publication Critical patent/MX2019008529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2019008529A 2017-01-19 2018-01-19 Peptidos mimeticos de apolipoproteina c-ii (apoc-ii). MX2019008529A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Publications (1)

Publication Number Publication Date
MX2019008529A true MX2019008529A (es) 2020-02-07

Family

ID=62908746

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008529A MX2019008529A (es) 2017-01-19 2018-01-19 Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).

Country Status (14)

Country Link
US (2) US11136372B2 (cg-RX-API-DMAC7.html)
EP (1) EP3571216B1 (cg-RX-API-DMAC7.html)
JP (2) JP7353973B2 (cg-RX-API-DMAC7.html)
KR (1) KR102700862B1 (cg-RX-API-DMAC7.html)
CN (1) CN110831957B (cg-RX-API-DMAC7.html)
AU (1) AU2018210404B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019014707A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050106A1 (cg-RX-API-DMAC7.html)
IL (2) IL268093B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019008529A (cg-RX-API-DMAC7.html)
NZ (1) NZ755599A (cg-RX-API-DMAC7.html)
SG (2) SG11201906422VA (cg-RX-API-DMAC7.html)
TW (2) TW202130652A (cg-RX-API-DMAC7.html)
WO (1) WO2018136803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018210404B2 (en) 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
US20240309065A1 (en) * 2021-06-23 2024-09-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Short apoc-ii mimetic peptides and methods of use
CN119233984A (zh) * 2022-05-05 2024-12-31 美国政府(由卫生和人类服务部的部长所代表) 短载脂蛋白e模拟肽及其使用方法
US20240043499A1 (en) * 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
EP1706131A4 (en) * 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
AU2005214225B2 (en) * 2004-02-19 2010-05-20 Banyu Pharmaceutical Co., Ltd. Novel sulfone amide derivative
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
CN102753576A (zh) * 2009-09-30 2012-10-24 首尔大学教产学协力团 载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
US10087234B2 (en) 2012-11-06 2018-10-02 Les Hopitaux Universitaires De Geneve Mimetic peptides
AU2018210404B2 (en) 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Also Published As

Publication number Publication date
KR20190121305A (ko) 2019-10-25
IL268093B1 (en) 2024-03-01
TW202130652A (zh) 2021-08-16
CN110831957A (zh) 2020-02-21
WO2018136803A8 (en) 2019-08-01
EP3571216B1 (en) 2026-05-27
US20210324043A1 (en) 2021-10-21
US11827690B2 (en) 2023-11-28
JP7353973B2 (ja) 2023-10-02
US11136372B2 (en) 2021-10-05
AU2018210404B2 (en) 2022-01-27
WO2018136803A1 (en) 2018-07-26
JP2023116739A (ja) 2023-08-22
TW201835097A (zh) 2018-10-01
AU2018210404A1 (en) 2019-08-08
SG10201911974UA (en) 2020-02-27
CN110831957B (zh) 2024-02-09
KR102700862B1 (ko) 2024-08-30
EP3571216C0 (en) 2026-05-27
NZ755599A (en) 2022-12-23
TWI788323B (zh) 2023-01-01
EP3571216A4 (en) 2020-11-04
SG11201906422VA (en) 2019-08-27
IL279831A (en) 2021-03-01
CA3050106A1 (en) 2018-07-26
BR112019014707A2 (pt) 2020-04-07
IL268093B2 (en) 2024-07-01
JP2020511425A (ja) 2020-04-16
US20200140522A1 (en) 2020-05-07
IL268093A (en) 2019-09-26
EP3571216A1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
CO2019009234A2 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
EP3365354C0 (en) Peptides and peptidomimethics in combination with T-cell activating agents and/or checkpoint inhibitors for the treatment of cancer
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
EA201792245A1 (ru) Биоконъюгаты и их применения
MX367600B (es) Transportador de la barrera hematoencefálica.
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
IL268874A (en) Peptides and methods for the treatment of diabetes
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
WO2018136803A8 (en) Apoc-ii mimetic peptides
IL275340A (en) Peptides and other active compounds to treat pain and increase pain sensitivity
JOP20200329A1 (ar) بروتينات وشظايا سائدة مناعيا في التصلب المتعدد
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
SG11202006669RA (en) Peptides and uses thereof
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
SG11201909851SA (en) Peptide for inducing regeneration of tissue, and use thereof
IL290643A (en) Peptides for transport and methods of using them
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
EP3628048A4 (en) PEPTIDES FOR CANCER TREATMENT
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
SG11202007887VA (en) Cyclic peptides and uses thereof
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
EA201991491A1 (ru) Миметические пептиды apoc-ii
EP3947418C0 (en) PEPTIDES AND THEIR USE
SG11202101090RA (en) Cdca1-derived peptide and vaccine containing same

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH